Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP

[1]  W. Choi,et al.  Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy , 2015, Modern Pathology.

[2]  K. Young,et al.  MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management , 2015, Oncotarget.

[3]  W. Choi,et al.  Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions , 2015, Modern Pathology.

[4]  L. Medeiros,et al.  MYC Cytogenetic Status Correlates With Expression and Has Prognostic Significance in Patients With MYC/BCL2 Protein Double-positive Diffuse Large B-cell Lymphoma , 2015, The American journal of surgical pathology.

[5]  W. Choi,et al.  Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma , 2015, Oncotarget.

[6]  K. Young,et al.  Genetic lesions in diffuse large B-cell lymphomas. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Y. Oki,et al.  A clinician's guide to double hit lymphomas , 2015, British journal of haematology.

[8]  A. Rosenwald,et al.  Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma , 2015, Leukemia.

[9]  L. Staudt,et al.  Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. , 2015, Blood.

[10]  W. Choi,et al.  Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma , 2015, Oncotarget.

[11]  A. Rosenwald,et al.  Diffuse Large B-cell Lymphomas of Immunoblastic Type Are a Major Reservoir for MYC-IGH Translocations , 2015, The American journal of surgical pathology.

[12]  W. Chan,et al.  MYC and BCL2 protein expression predicts survival in patients with diffuse large B‐cell lymphoma treated with rituximab , 2014, British journal of haematology.

[13]  R. Spang,et al.  Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma , 2014, Haematologica.

[14]  A. Melnick,et al.  Cooperative transcriptional repression by BCL6 and BACH2 in germinal center B-cell differentiation. , 2014, Blood.

[15]  A. Rosenwald,et al.  Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. , 2013, Blood.

[16]  W. Choi,et al.  MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. , 2013, Blood.

[17]  J. Briones,et al.  MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy , 2013, Haematologica.

[18]  W. Choi,et al.  MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. , 2013, Blood.

[19]  Joonsoo Kang,et al.  SMAD regulatory networks construct a balanced immune system , 2013, Immunology.

[20]  W. Choi,et al.  CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. , 2013, Blood.

[21]  C. Thieblemont,et al.  MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future? , 2013, Blood.

[22]  A. Rosenwald,et al.  MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. , 2013, Blood.

[23]  W. Choi,et al.  Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study , 2013, Haematologica.

[24]  C. Leslie,et al.  BCL6 positively regulates AID and germinal center gene expression via repression of miR-155 , 2012, The Journal of experimental medicine.

[25]  Francis A. Cucinotta,et al.  Novel Smad proteins localize to IR-induced double-strand breaks: interplay between TGFβ and ATM pathways , 2012, Nucleic acids research.

[26]  W. Choi,et al.  Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. , 2012, Blood.

[27]  Ash A. Alizadeh,et al.  Role of Smad Proteins in Resistance to BMP-Induced Growth Inhibition in B-Cell Lymphoma , 2012, PloS one.

[28]  M. Pfreundschuh.  Growing importance of MYC/BCL2 immunohistochemistry in diffuse large B-cell lymphomas. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  L. Staudt,et al.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Charles Y. Lin,et al.  Transcriptional Amplification in Tumor Cells with Elevated c-Myc , 2012, Cell.

[31]  D. Green,et al.  c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem Cells , 2012, Cell.

[32]  K. Rajewsky,et al.  MYC is essential for the formation and maintenance of germinal centers , 2012, Nature Immunology.

[33]  K. Dybkær,et al.  Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study , 2012, Leukemia.

[34]  M. Benekli,et al.  Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B‐cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab , 2012, Cancer.

[35]  P. L. Bergsagel,et al.  Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. , 2012, Blood.

[36]  K. Young,et al.  Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  G. Brede,et al.  Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC , 2012, Leukemia.

[38]  S. Monti,et al.  Immunohistochemical Detection of MYC-driven Diffuse Large B-Cell Lymphomas , 2012, PloS one.

[39]  K. Young,et al.  High Levels of Nuclear MYC Protein Predict the Presence of MYC Rearrangement in Diffuse Large B-cell Lymphoma , 2012, The American journal of surgical pathology.

[40]  A. Ariza,et al.  Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas , 2011, Histopathology.

[41]  S. Orkin,et al.  MicroRNA-21 Limits In Vivo Immune Response-Mediated Activation of the IL-12/IFN-γ Pathway, Th1 Polarization, and the Severity of Delayed-Type Hypersensitivity , 2011, The Journal of Immunology.

[42]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[43]  J. Läuter,et al.  MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4 , 2011, Oncogene.

[44]  D. Pisano,et al.  MicroRNA signatures in B-cell lymphomas , 2010, Blood Cancer Journal.

[45]  S. Barrans,et al.  Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  D. Felsher.  MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms. , 2010, Genes & cancer.

[47]  R. Gascoyne,et al.  MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.

[48]  R. Gascoyne,et al.  Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. , 2009, Blood.

[49]  E. Obermann,et al.  Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment , 2009, Journal of Clinical Pathology.

[50]  L. Mazzucchelli,et al.  BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. , 2009, Human pathology.

[51]  Michel C Nussenzweig,et al.  MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation. , 2008, Immunity.

[52]  F. Jardin,et al.  Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas , 2007, Leukemia.

[53]  E. Schuuring,et al.  Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  Richard Simon,et al.  Molecular diagnosis of Burkitt's lymphoma. , 2006, The New England journal of medicine.

[55]  R. Spang,et al.  A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. , 2006, The New England journal of medicine.

[56]  W. Choi,et al.  Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP , 2014, Modern Pathology.

[57]  G. Brede,et al.  Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC , 2012, Leukemia.

[58]  M. Henriksson,et al.  MYC in oncogenesis and as a target for cancer therapies. , 2010, Advances in cancer research.